Salisbury Visiting Nurse Assoc | |
30a Salmon Kill Rd, Salisbury, Connecticut 6068 | |
(860) 435-0816 | |
Name | Salisbury Visiting Nurse Assoc |
---|---|
Location | 30a Salmon Kill Rd, Salisbury, Connecticut |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
Medicare ID | 77112 |
Ownership Type | Voluntary Non-profit - Other |
Service Area Zip Codes | 6018, 6024, 6031, 6039, 6058, 6068, 6069, 6079, 6753, 6754, 6756, 6757, 6785, 6796 |
NPI Number | 1922000884 |
Organization Name | SALISBURY VISITING NURSE ASSOCIATION, INC. |
Address | 30a Salmon Kill Rd, Salisbury, CT 06068 |
Phone Number | 860-435-0816 |
News Archive
The anticoagulants currently used to prevent strokes in dialysis patients with atrial fibrillation do not provide adequate protection for this group.
Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.
The National Reference Centre for Parasitology (NRCP), based at the MUHC, is developing a comprehensive and inexpensive blood safety test that will allow clinicians to check for all major parasitic diseases in patients' blood.
› Verified 3 days ago
Quality Rating: |
News Archive
The anticoagulants currently used to prevent strokes in dialysis patients with atrial fibrillation do not provide adequate protection for this group.
Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.
The National Reference Centre for Parasitology (NRCP), based at the MUHC, is developing a comprehensive and inexpensive blood safety test that will allow clinicians to check for all major parasitic diseases in patients' blood.
› Verified 3 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 98.5 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 100 | 98.6 |
How often the home health team checked patients’ risk of falling | 100 | 99.6 |
How often the home health team checked patients for depression | 91.5 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 79.7 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 78.8 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 93.8 | 96.4 |
News Archive
The anticoagulants currently used to prevent strokes in dialysis patients with atrial fibrillation do not provide adequate protection for this group.
Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.
The National Reference Centre for Parasitology (NRCP), based at the MUHC, is developing a comprehensive and inexpensive blood safety test that will allow clinicians to check for all major parasitic diseases in patients' blood.
› Verified 3 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 74.8 | 79.6 |
How often patients got better at getting in and out of bed | 79 | 81.1 |
How often patients got better at bathing | 72.1 | 82.3 |
How often patients’ breathing improved | 68.7 | 82.8 |
How often patients’ wounds improved or healed after an operation | 95.2 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 67.4 | 75 |
How often home health patients had to be admitted to the hospital | 14.4 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 14.2 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 93.5 | 94 |
News Archive
The anticoagulants currently used to prevent strokes in dialysis patients with atrial fibrillation do not provide adequate protection for this group.
Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.
The National Reference Centre for Parasitology (NRCP), based at the MUHC, is developing a comprehensive and inexpensive blood safety test that will allow clinicians to check for all major parasitic diseases in patients' blood.
› Verified 3 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | |
Health team communicated well with them | |
Health team discussed medicines, pain, and home safety | |
How patients rated overall care from agency |
News Archive
The anticoagulants currently used to prevent strokes in dialysis patients with atrial fibrillation do not provide adequate protection for this group.
Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.
The National Reference Centre for Parasitology (NRCP), based at the MUHC, is developing a comprehensive and inexpensive blood safety test that will allow clinicians to check for all major parasitic diseases in patients' blood.
› Verified 3 days ago
The patient survey data of Salisbury Visiting Nurse Assoc is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 88 | 88 |
Percent of patients who reported that their home health team communicated well with them | 87 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 84 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 88 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 82 | 78 |
News Archive
The anticoagulants currently used to prevent strokes in dialysis patients with atrial fibrillation do not provide adequate protection for this group.
Oncolytics Biotech Inc. announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572).
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.
The National Reference Centre for Parasitology (NRCP), based at the MUHC, is developing a comprehensive and inexpensive blood safety test that will allow clinicians to check for all major parasitic diseases in patients' blood.
› Verified 3 days ago
Salisbury Visiting Nurse Assoc Location: 30a Salmon Kill Rd, Salisbury, Connecticut 6068 Ratings: Phone: (860) 435-0816 |